{"database": "openregs", "table": "federal_register", "rows": [["2016-15663", "Bioequivalence Recommendations for Paliperidone Palmitate; Draft Guidance for Industry; Availability", "Notice", "The Food and Drug Administration (FDA) is announcing the availability of a revised draft guidance for industry on generic paliperidone palmitate extended-release injectable suspension, entitled \"Draft Guidance on Paliperidone Palmitate.\" The recommendations provide specific guidance on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for paliperidone palmitate extended-release injectable suspension.", "2016-07-01", 2016, 7, "https://www.federalregister.gov/documents/2016/07/01/2016-15663/bioequivalence-recommendations-for-paliperidone-palmitate-draft-guidance-for-industry-availability", "https://www.govinfo.gov/content/pkg/FR-2016-07-01/pdf/2016-15663.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA) is announcing the availability of a revised draft guidance for industry on generic paliperidone palmitate extended-release injectable suspension, entitled \"Draft Guidance on Paliperidone Palmitate.\" The...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2016-15663"], "units": {}, "query_ms": 5.676159169524908, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}